Literature DB >> 24701471

Glycosylated Haemoglobin (HbA1c) - A Marker of Circulating Lipids in Type 2 Diabetic Patients.

Prabhavathi K1, Kirthana Kunikullaya U2, Jaisri Goturu3.   

Abstract

BACKGROUND: Diabetic patients with concomitant dyslipidemia are often soft targets for cardiovascular disease and deaths. An early intervention to normalize circulating lipids has been shown to reduce cardiovascular morbidity and mortality. Glycosylated hemoglobin (HbA1c) is routinely used as a marker to indicate long-term glycemic control. AIM: Our aim was to test whether HbA1c can serve as a marker of circulating lipids among Type 2 diabetic patients.
METHODS: The sera of 130 Type 2 diabetic patients was analyzed for fasting blood sugar (FBS), HbA1c and lipid profile consisting of total cholesterol (TC), triglycerides (TG), High-density Lipoprotein (HDL) cholesterol and LDL cholesterol. We divided the subjects based on their glycemic index into three groups; HbA1c< 6% as good, HbA1c>6% - <9% as poor and HbA1c>9% as worst glycemic control. One-way analysis of variance (ANOVA) and post-hoc Dunnett's multiple comparison tests was used to examine the significance levels for various biochemical parameters in age-categorized groups.
RESULTS: The mean ± SD levels of HbA1c was significantly higher in females (8.598 ± 2.284 %) compared to males (7.323±2.18 %). Older patients had HbA1c, FBS and lipid profile levels similar to younger ones. HbA1c showed direct and significant correlations with cholesterol, TG and LDL. Univariate analysis showed that HbA1c was a good predictor of circulating lipid levels.
CONCLUSION: The study indicates the usefulness of HbA1c as a marker for lipid profile for screening of diabetic patients at high risk of developing cardiovascular diseases.

Entities:  

Keywords:  Coronary artery disease; Dyslipidemia; Glycemic control

Year:  2014        PMID: 24701471      PMCID: PMC3972563          DOI: 10.7860/JCDR/2014/7742.3996

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  33 in total

1.  Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study.

Authors:  Elizabeth Selvin; Josef Coresh; Sherita H Golden; Frederick L Brancati; Aaron R Folsom; Michael W Steffes
Journal:  Arch Intern Med       Date:  2005-09-12

2.  An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure.

Authors:  Shervin Eshaghian; Tamara B Horwich; Gregg C Fonarow
Journal:  Am Heart J       Date:  2006-01       Impact factor: 4.749

Review 3.  Management of dyslipidemia in NIDDM.

Authors:  A Garg; S M Grundy
Journal:  Diabetes Care       Date:  1990-02       Impact factor: 19.112

4.  Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up.

Authors:  M Hanefeld; S Fischer; U Julius; J Schulze; U Schwanebeck; H Schmechel; H J Ziegelasch; J Lindner
Journal:  Diabetologia       Date:  1996-12       Impact factor: 10.122

5.  Association of hemoglobin A(1c) level with the severity of coronary artery disease in patients with diabetes mellitus.

Authors:  Gautham Ravipati; Wilbert S Aronow; Chul Ahn; Kumbar Sujata; Leonardo N Saulle; Melvin B Weiss
Journal:  Am J Cardiol       Date:  2006-02-13       Impact factor: 2.778

6.  Lipid profile correlates with glycemic control in young patients with type 1 diabetes mellitus.

Authors:  Ana Marice Ladeia; Luis Adan; Ana Claudia Couto-Silva; Angela Hiltner; Armênio C Guimarães
Journal:  Prev Cardiol       Date:  2006

7.  Coronary heart disease, type 2 diabetes mellitus and cardiovascular disease risk factors: a study on a middle-aged and elderly population.

Authors:  R Giansanti; R A Rabini; F Romagnoli; D Fumelli; P Sorichetti; M Boemi; P Fumelli
Journal:  Arch Gerontol Geriatr       Date:  1999 Sep-Oct       Impact factor: 3.250

8.  A prospective study of the effect of 12 months treatment on serum lipids and apolipoproteins A-I and B in Type 2 (non-insulin-dependent) diabetes.

Authors:  K G Taylor; W G John; K A Matthews; A D Wright
Journal:  Diabetologia       Date:  1982-12       Impact factor: 10.122

9.  Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity.

Authors:  J L Witztum; E M Mahoney; M J Branks; M Fisher; R Elam; D Steinberg
Journal:  Diabetes       Date:  1982-04       Impact factor: 9.461

10.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

View more
  5 in total

1.  HbA1c as a Screening tool for Ketosis in Patients with Type 2 Diabetes Mellitus.

Authors:  Bing Zhu; Le Bu; Manna Zhang; Aaron M Gusdon; Liang Zheng; Sharvan Rampersad; Jue Li; Shen Qu
Journal:  Sci Rep       Date:  2016-12-23       Impact factor: 4.379

2.  Mediterranean dietary quality index and dietary phytochemical index among patients candidate for coronary artery bypass grafting (CABG) surgery.

Authors:  Mahdieh Abbasalizad Farhangi; Mahdi Najafi; Mohammad Asghari Jafarabadi; Leila Jahangiry
Journal:  BMC Cardiovasc Disord       Date:  2017-05-08       Impact factor: 2.298

3.  The association of dyslipidemia and obesity with glycated hemoglobin.

Authors:  Jayesh Sheth; Ankna Shah; Frenny Sheth; Sunil Trivedi; Nutan Nabar; Navneet Shah; Premal Thakor; Rama Vaidya
Journal:  Clin Diabetes Endocrinol       Date:  2015-06-23

4.  Phytate Decreases Formation of Advanced Glycation End-Products in Patients with Type II Diabetes: Randomized Crossover Trial.

Authors:  Pilar Sanchis; Rosmeri Rivera; Francisco Berga; Regina Fortuny; Miquel Adrover; Antonia Costa-Bauza; Felix Grases; Luis Masmiquel
Journal:  Sci Rep       Date:  2018-06-25       Impact factor: 4.379

5.  Efficacy of a Validated Yoga Protocol on Dyslipidemia in Diabetes Patients: NMB-2017 India Trial.

Authors:  Raghuram Nagarathna; Rahul Tyagi; Gurkeerat Kaur; Vetri Vendan; Ishwara N Acharya; Akshay Anand; Amit Singh; Hongasandra R Nagendra
Journal:  Medicines (Basel)       Date:  2019-10-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.